Sangamo Q4 2022 Earnings Report
Key Takeaways
Sangamo Therapeutics reported fourth quarter 2022 revenues of $27.2 million and a net loss of $52.0 million, or $0.32 per share. The company highlighted progress in its Fabry disease, renal transplant rejection, sickle cell disease, and hemophilia A programs, and provided initial financial guidance for 2023.
Reported compelling updated preliminary Phase 1/2 data showing extended clinical benefit for Fabry disease.
Progressed manufacturing and clinical activities ahead of anticipated Q2 dosing for Renal Transplant Rejection.
Presented promising 6-month data for first patient dosed with a product candidate manufactured using improved methods for Sickle cell disease.
Dosing in Phase 3 AFFINE trial expected to be complete by end of Q1 2023 for Hemophilia A.
Sangamo
Sangamo
Forward Guidance
Sangamo expects GAAP total operating expenses in the range of approximately $310 million to $330 million in 2023. Non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $35 million, are expected in the range of approximately $275 million to $295 million in 2023.